Bicyclic compound and use thereof for medical purposes
US-10940134-B2 · Mar 9, 2021 · US
Bicyclic compound and use thereof for medical purposes
US11617733B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11617733-B2 |
| Application number | US-202117149327-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 14, 2021 |
| Priority date | Jul 28, 2009 |
| Publication date | Apr 4, 2023 |
| Grant date | Apr 4, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating a human with glaucoma, comprising administering an effective amount of the compound of formula (I), wherein the administering lowers intraocular pressure of the human.
Assignees
Inventors
Classifications
Eye · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
- C07D313/06Primary
condensed with carbocyclic rings or ring systems · CPC title
having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11617733B2 cover?
- Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., i…
- Who is the assignee on this patent?
- Ono Pharmaceutical Co
- What technology area does this patent fall under?
- Primary CPC classification C07D313/06. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).